[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6183 followers
Created: 2025-07-23 13:17:46 UTC

📊 Senores Pharmaceuticals Q1 FY26: Strong Growth in Regulated & Emerging Markets | MCap XXXXXXXX Cr

- Launched X own ANDA products in Regulated Markets; received approval for X more.
- Strong pipeline: XX Approved ANDA products & XX in Pipeline (Regulated Markets).
- Emerging Markets presence: XXX Registered products & XXX under Registration across 40+ countries.
- Q1 FY26 Operating Cash Flow: Positive at ₹11 Cr.
- Consolidated Total Income: ₹141.35 Cr (Revenue from Operations: ₹137.99 Cr).
- Regulated Markets Revenue: ₹90 Cr (69% Y-o-Y growth), EBITDA Margin: 35.5%.
- Emerging Markets Revenue: ₹29 Cr (32% Y-o-Y growth), EBITDA Margin: 6%.
- Net PAT: ₹21.18 Cr (15% margin).
- EBITDA: ₹32.49 Cr (23% margin).
- IPO funds: ₹240.99 Cr utilized out of ₹500 Cr (₹259.01 Cr remaining).
- New appointment: Mr. Jignesh Shashikant Desai as President-Finance (effective July 23, 2025).

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/Gwi4TRObUAAEx1B.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948009643789410449/c:line.svg)

**Related Topics**
[cash flow](/topic/cash-flow)
[countries](/topic/countries)
[approved](/topic/approved)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1948009643789410449)